Strong Q1 results with 11% YoY revenue growth, significant net loss reduction, FDA clearance for new product, raised full-year guidance, and positive CEO outlook for accelerated growth through 2026-2027. Stock gained 19.72% on the news.
Articles that tag SIBN but are mainly about other companies.
Signed distribution agreement with Smith+Nephew for iFuse TORQ portfolio, gaining access to Smith+Nephew's extensive orthopaedic distribution network and customer base, which should expand market reach.
Established distribution agreement with Smith+Nephew for their iFuse TORQ portfolio, gaining access to Smith+Nephew's extensive distribution network and market reach.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
